ABUS

Arbutus Biopharma Corp buybacks.

BuybackStocks tracks every share-repurchase filing Arbutus Biopharma Corp (ABUS) submits to SEC EDGAR. Current board authorization stands at $230M. Below: 2 editorial summary of recent filings, plus quarterly execution detail from SEC XBRL data.

Authorization$230M
Filings tracked2

Recent buyback filings

Every Form 8-K authorization, 10-Q issuer-purchase table, and 10-K disclosure for Arbutus Biopharma Corp, sourced from SEC EDGAR and editorialized by BuybackStocks.

8-K · 2026-08-12 New authorization

Arbutus Biopharma Corp — $230M

View the full editorial summary with source quote, key facts, and what-this-means analysis.
8-K · 2026-07-16 New authorization

Arbutus Biopharma Corp — $230M

View the full editorial summary with source quote, key facts, and what-this-means analysis.

Related

See the wider context for this program: the Top 20 buybacks of 2026, our glossary of repurchase concepts, or all recent SEC filings we've covered.